[Pharm-policy] BMS press releast on ddI and d4T

[love@cptech.org]

http://www.bms.com/landing/data/index.html


 Bristol-Myers Squibb Announces Accelerated Effort To Fight HIV/AIDS In
Africa 
 Company launches four-part plan: 

AIDS DRUGS BELOW COST
Bristol-Myers Squibb will make Videx® (didanosine) and Zerit®
(stavudine), its two medicines for HIV/AIDS, available in poor countries
in Africa at 15 cents per day for Zerit and 80 cents per day for Videx
-- prices below their cost to the company.


TRANSPARENT PRICING FOR AIDS DRUGS IN AFRICA
The prices of the products offered under the ACCESS program will be
fully public.


$115 MILLION IN SECURE THE FUTURE™ PHILANTHROPY
Bristol-Myers Squibb pledges an additional $15 million in funds for our
SECURE THE FUTURE initiative in southern Africa, raising the program
total to $115 million.


EMERGENCY PATENT RELIEF
Bristol-Myers Squibb has made an agreement with Yale University to grant
a free license under the patent for Zerit (rights to which are owned by
Yale and Bristol-Myers Squibb) to treat AIDS in sub-Saharan Africa.